dc.contributor.author | Kotteas, E. A. | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.creator | Kotteas, E. A. | en |
dc.creator | Pavlidis, Nicholas | en |
dc.date.accessioned | 2018-06-22T09:53:50Z | |
dc.date.available | 2018-06-22T09:53:50Z | |
dc.date.issued | 2015 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/42050 | |
dc.description.abstract | Merkel cell nodal carcinoma of unknown primary (MCCUP) is a rare neuroendocrine tumour with distinct clinical and biological behaviour. We conducted a review of retrospective data extracted from 90 patients focusing on the management and outcome of this disease. We also compared life expectancy of these patients with the outcome of patients with known Merkel primaries and with neuroendocrine cancers of unidentifiable primary. There is a limited body of data for this type of malignancy, however, patients with Merkel cell nodal carcinoma of unknown primary site, seem to have better survival when treated aggressively than patients with cutaneous Merkel tumours of the same stage and equal survival with patients with low-grade neuroendocrine tumour of unknown origin. The lack of prospective trials, and the inadequate data, hamper the management of these tumours. Establishment of treatment guidelines is urgently needed. © 2014 Elsevier Ireland Ltd. | en |
dc.language.iso | eng | en |
dc.source | Critical reviews in oncology/hematology | en |
dc.subject | Review | en |
dc.subject | Cisplatin | en |
dc.subject | Etoposide | en |
dc.subject | Human | en |
dc.subject | Neoplasms | en |
dc.subject | Humans | en |
dc.subject | Cancer survival | en |
dc.subject | Carboplatin | en |
dc.subject | Computer assisted tomography | en |
dc.subject | Platinum derivative | en |
dc.subject | Prognosis | en |
dc.subject | Retrospective study | en |
dc.subject | Cancer staging | en |
dc.subject | Overall survival | en |
dc.subject | Outcome assessment | en |
dc.subject | Carcinoma | en |
dc.subject | Skin neoplasms | en |
dc.subject | Mortality | en |
dc.subject | Meta analysis | en |
dc.subject | Sex difference | en |
dc.subject | Immunohistochemistry | en |
dc.subject | Protein expression | en |
dc.subject | Cancer grading | en |
dc.subject | Histopathology | en |
dc.subject | Lymph node dissection | en |
dc.subject | Lymph node metastasis | en |
dc.subject | Survival time | en |
dc.subject | High risk population | en |
dc.subject | Cancer therapy | en |
dc.subject | Treatment response | en |
dc.subject | Cancer of unknown primary site | en |
dc.subject | Unknown primary | en |
dc.subject | Cytokeratin 20 | en |
dc.subject | Cytokeratin 7 | en |
dc.subject | Unknown primary | en |
dc.subject | Neuroendocrine tumor | en |
dc.subject | Cd56 antigen | en |
dc.subject | Computer assisted emission tomography | en |
dc.subject | Stem cell factor receptor | en |
dc.subject | Neuroendocrine tumors | en |
dc.subject | Adjuvant chemoradiotherapy | en |
dc.subject | Cancer morphology | en |
dc.subject | Chromogranin a | en |
dc.subject | Disease management | en |
dc.subject | Life expectancy | en |
dc.subject | Local excision | en |
dc.subject | Merkel carcinoma | en |
dc.subject | Merkel cell | en |
dc.subject | Merkel cell nodal carcinoma of unknown primary | en |
dc.subject | Merkel cell tumor | en |
dc.subject | Neurofilament protein | en |
dc.subject | Patient outcome assessment | en |
dc.subject | Recurrence free survival | en |
dc.subject | Secondary | en |
dc.title | Neuroendocrine Merkel cell nodal carcinoma of unknown primary site: Management and outcomes of a rare entity | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1016/j.critrevonc.2014.12.005 | |
dc.description.volume | 94 | |
dc.description.issue | 1 | |
dc.description.startingpage | 116 | |
dc.description.endingpage | 121 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |